- Home
- SLNO vs GPCR Comparison
SLNO vs GPCR Comparison
Compare SLNO & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLNO
- GPCR
- Stock Information
- Founded
- SLNO 1999
- GPCR 2016
- Country
- SLNO United States
- GPCR United States
- Employees
- SLNO N/A
- GPCR N/A
- Industry
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- GPCR
- Sector
- SLNO Health Care
- GPCR
- Exchange
- SLNO Nasdaq
- GPCR Nasdaq
- Market Cap
- SLNO 1.9B
- GPCR 1.8B
- IPO Year
- SLNO 2014
- GPCR 2023
- Fundamental
- Price
- SLNO $53.89
- GPCR $39.35
- Analyst Decision
- SLNO Strong Buy
- GPCR Buy
- Analyst Count
- SLNO 7
- GPCR 6
- Target Price
- SLNO $68.71
- GPCR $87.83
- AVG Volume (30 Days)
- SLNO 803.1K
- GPCR 661.4K
- Earning Date
- SLNO 11-05-2024
- GPCR 11-12-2024
- Dividend Yield
- SLNO N/A
- GPCR N/A
- EPS Growth
- SLNO N/A
- GPCR N/A
- EPS
- SLNO N/A
- GPCR N/A
- Revenue
- SLNO N/A
- GPCR N/A
- Revenue This Year
- SLNO N/A
- GPCR N/A
- Revenue Next Year
- SLNO N/A
- GPCR N/A
- P/E Ratio
- SLNO N/A
- GPCR N/A
- Revenue Growth
- SLNO N/A
- GPCR N/A
- 52 Week Low
- SLNO $21.30
- GPCR $26.61
- 52 Week High
- SLNO $56.81
- GPCR $75.02
- Technical
- Relative Strength Index (RSI)
- SLNO 57.97
- GPCR 46.51
- Support Level
- SLNO $53.02
- GPCR $38.00
- Resistance Level
- SLNO $54.86
- GPCR $40.34
- Average True Range (ATR)
- SLNO 2.13
- GPCR 2.06
- MACD
- SLNO 0.23
- GPCR -0.24
- Stochastic Oscillator
- SLNO 68.82
- GPCR 45.06
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.